F. Damm
4 Papers
1 Citations
F. Damm is an academic researcher. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 1, co-authored 4 publications.
Chat about Author
Papers
S130: npm1 mutated aml: impact of co-mutational patterns - results of the european harmony alliance
Alberto Hernandez-Sanchez,Á. Villaverde-Ramiro,J. Martinez Elicegui,T. González,Alisha Benner,Eric Sträng,Giorgia Castellani,Caroline A. Heckman,Jurjen Versluis,María Abáigar,Marta Anna Sobas,Raul Azibeiro,L. Tur,P. Valk,Klaus H. Metzeler,Rodriguez Ayala,Daniele Dall'Olio,Jesse M. Tettero,Jorge Martínez-López,Hervé Dombret,Marta Pratcorona,F. Damm,Ken I. Mills,Jillian Mayer,Christian Thiede,Maria Teresa Voso,Guillermo Sanz,Filipe Calado,Konstanze Döhner,Verena I. Gaidzik,Michael Heuser,Torsten Haferlach,Amin T. Turki,Dirk Reinhardt,R. Villoria Medina,M van Speybroeck,Renate Schulze-Rath,Martje Barbus,John Butler,J.M. Hernández Rivas,B. J. Huntly,Gert J. Ossenkoppele,Hartmut Döhner,Lars Bullinger +43 more
TL;DR: Multivariate analysis of OS in N PM1mut AML identified the following independent prognostic factors: NPM1mut model (taking favorable group as reference, HR 1.6 for intermediate and HR 2.7 for adverse group, p<0.001); secondary or therapy-related AML; WBC at diagnosis >100x103/μL; and age >60 years.
2
Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
Marta Anna Sobas,Angela Villaverde Ramiro,Alberto Hernández Sánchez,J. Martinez Elicegui,Teresa González,Raúl Azibeiro Melchor,María Abáigar,L. Tur,Daniele Dall'Olio,Eric Sträng,Jesse M. Tettero,Castellani Gastone,Axel Benner,Konstanze Döhner,Christian Thiede,Amin T. Turki,Klaus H. Metzeler,Torsten Haferlach,F. Damm,Rosa Ayala,Joaquin Martinez-Lopez,Ken I. Mills,Jorge Sierra,Sören Lehmann,Matteo G. Della Porta,Jiri Mayer,Dirk Reinhardt,R. Villoria Medina,Renate Schulze-Rath,Martje Barbus,Jesús M. Hernández-Rivas,Brian J. P. Huntly,Gert J. Ossenkoppele,Hartmut Dohner,Lars Bullinger +34 more
TL;DR: In this paper , the authors analyzed changes in outcome of AML patients treated between 1997-2016 prior to the approval of novel drugs, in order to better understand important factors contributing to patient outcome that might also contribute to the efficacy novel treatment approaches.
1
S101: genetic and epigenetic factors driving primary mediastinal b-cell lymphoma pathogenesis and outcome
Dominik Noerenberg,Franziska Briest,Cornelius Hennch,K. Yoshida,J. Nimo,Raphael Hablesreiter,Y. Takeuchi,Daniel Sasca,H. Ueno,Larry Mansouri,Y. Inoue,L. Wiegand,Annette M. Staiger,Beatrice Casadei,Marita Ziepert,Fazila Asmar,Penelope Korkolopoulou,Mary Kirchner,P. Mertins,J. Weiner,E. Tóth,Therese M Weber,Annegret Warth,Tanja Schneider,Rose-Marie Amini,Wolfram Klapper,Micheal Hummel,Viola Poeschel,George Kanellis,Andreas Rosenwald,Gerhard Held,E. Campo,Kostas Stamatopoulos,Ioannis Anagnostopoulos,Lars Bullinger,N. Goldschmidt,Pier Luigi Zinzani,C. Bödor,Rebecka Rosenquist,T.P. Vassilakopoulos,German Ott,Sara Ogawa,F. Damm +42 more
TL;DR: In this paper , a large-scale genetic investigation of primary mediastinal large B-cell lymphoma (PMBCL) patients was carried out using CRISPR/Cas9 engineered cell lines.
1
Rapid and Reproducible Karyotyping with Nanopore Sequencing in AML Patients
Michael Heuser,Nouraldin Damrah,Razif Gabdoulline,Courteney Lai,Eric Sträng,Mustafa Salim,Gudrun Göhring,Yvonne Lisa Behrens,E. Jahn,Martin Wichmann,Jens-Florian Schrezenmeier,Yasmine Alwie,Joerg Westermann,F. Damm,Brigitte Schlegelberger,Frank G. Rücker,Hartmut Döhner,Arnold Ganser,Felicitas Thol,Olga Blau,Konstanze Döhner,Lars Bullinger,Anna Dolnik +22 more
TL;DR: In this paper , the authors evaluated low coverage whole genome sequencing (WGS) of acute myeloid leukemia (AML) patients using long read Oxford Nanopore Technology (ONTseq) for karyotyping and compared the results and the frequency of patients with myelodysplasia-related cytogenetic abnormalities according to previous and current AML classifications with conventional cytogenetics.